-
-
Scientific American (December 15, 2022) First ‘Vagina-on-a-Chip’ Will Help Researchers Test Drugs
Scientists have developed what they say is the world’s first “vagina-on-a-chip,” which uses living cells and bacteria to mimic the microbial environment of the human vagina. It could help to test drugs against bacterial vaginosis (BV), a common microbial imbalance that makes millions of people more susceptible to sexually transmitted diseases and puts them at risk of preterm delivery when pregnant.
Forbes (December 14, 2022) How Taking Smart Risks Makes Drug Development Less Speculative
Drugmakers find that taking a risk on new technology can actually help them reduce their risk across other aspects of the R&D pipeline, as novel tools and applications help them make better decisions earlier in the process and improve overall translatability.
Select Science (December 14, 2022) Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce
“By combining Cellesce’s expertise in producing industrial-scale PDOs with Molecular Devices’ market-leading end-to-end solutions for automated organoid screening, we will enable customers to accomplish advanced 3D biology research with a commercial offering that’s never been available before from one provider,” said Susan Murphy, President of Molecular Devices. “This enabling technology will make over 100,000 compound primary screens with PDOs a reality and will accelerate industry adoption of organoids.”
The Independent (December 12, 2022) Scientists create ‘vagina on a chip’ to test drugs against infection
Scientists have created a model “vagina on a chip” using cells grown inside silicone rubber chips – an advance that could help better understand the effects of bacterial communities on vaginal health.
Vox (December 11, 2022) Neuralink shows what happens when you bring “move fast and break things” to animal research
Animal testing has led to scientific breakthroughs we all benefit from, but it’s also costly and slow, and it often fails — according to the NIH, 95 percent of pharmaceutical drugs that work in animal trials fail in human trials. Some in the science community wonder why we’re betting so much of the future of medicine on mice and rats. There’s also a growing chorus of voices — not just activists and law professors, but also drug developers, researchers, veterinarians, and entrepreneurs — arguing that a new suite of high-tech, non-animal alternative methods could lead to faster, safer, and more ethical drug development and product testing. Musk has always viewed himself as a change agent, a disruptor, and Neuralink is part of that. But in allegedly mistreating animals in research, his company is all too conventional.
-
- You must be logged in to reply to this topic.